Crolibulin is primarily investigated for its potential application in cancer treatment, particularly as a vascular disrupting agent. It works by targeting and destabilizing the existing blood vessels that supply tumors, effectively cutting off their nutrient and oxygen supply. This mechanism can lead to the shrinkage of tumors and is being explored in clinical trials for various types of cancer, including solid tumors such as brain, lung, and skin cancers. Its ability to selectively disrupt tumor vasculature while sparing normal tissues makes it a promising candidate for combination therapies with other anticancer agents, enhancing overall treatment efficacy.